JP2023129433A5 - - Google Patents

Download PDF

Info

Publication number
JP2023129433A5
JP2023129433A5 JP2023106715A JP2023106715A JP2023129433A5 JP 2023129433 A5 JP2023129433 A5 JP 2023129433A5 JP 2023106715 A JP2023106715 A JP 2023106715A JP 2023106715 A JP2023106715 A JP 2023106715A JP 2023129433 A5 JP2023129433 A5 JP 2023129433A5
Authority
JP
Japan
Prior art keywords
antibody molecule
seq
nos
pharmaceutical composition
treg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023106715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023129433A (ja
Filing date
Publication date
Priority claimed from GBGB1712032.0A external-priority patent/GB201712032D0/en
Application filed filed Critical
Publication of JP2023129433A publication Critical patent/JP2023129433A/ja
Publication of JP2023129433A5 publication Critical patent/JP2023129433A5/ja
Priority to JP2025116576A priority Critical patent/JP2025157343A/ja
Pending legal-status Critical Current

Links

JP2023106715A 2017-07-26 2023-06-29 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用 Pending JP2023129433A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116576A JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1712032.0A GB201712032D0 (en) 2017-07-26 2017-07-26 Antibodies and uses thereof
GB1712032.0 2017-07-26
JP2020526685A JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用
PCT/EP2018/070359 WO2019020774A2 (en) 2017-07-26 2018-07-26 NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526685A Division JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116576A Division JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Publications (2)

Publication Number Publication Date
JP2023129433A JP2023129433A (ja) 2023-09-14
JP2023129433A5 true JP2023129433A5 (https=) 2024-06-20

Family

ID=59771732

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526685A Active JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用
JP2023106715A Pending JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526685A Active JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびTreg枯渇抗体と免疫刺激性抗体との併用

Country Status (8)

Country Link
US (2) US11447549B2 (https=)
EP (1) EP3658587A2 (https=)
JP (3) JP7458973B2 (https=)
CN (1) CN111108124B (https=)
AU (1) AU2018305209B2 (https=)
CA (1) CA3070290A1 (https=)
GB (1) GB201712032D0 (https=)
WO (1) WO2019020774A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220032642A (ko) * 2016-04-07 2022-03-15 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
PL3623798T3 (pl) * 2018-09-13 2022-03-28 Euroimmun Medizinische Labordiagnostika Ag Sposób i urządzenie do wykrywania i przedstawiania obrazu immunofluorescencyjnego próbki biologicznej
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122779B1 (en) * 2014-03-24 2019-05-22 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
WO2015188047A1 (en) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對icos之抗體
HK1251474A1 (zh) * 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
KR20220032642A (ko) * 2016-04-07 2022-03-15 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
BR112019025913A2 (pt) 2017-06-09 2020-06-30 Glaxosmithkline Intellectual Property Development Limited métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.

Similar Documents

Publication Publication Date Title
JP2023129433A5 (https=)
JP2020504723A5 (https=)
JP2022061993A5 (https=)
JP2020520665A5 (https=)
JP2020103301A5 (https=)
JP2021516976A5 (https=)
JP2021515566A5 (https=)
JP2020501531A5 (https=)
JP2021516973A5 (https=)
JP2021501162A5 (https=)
JP2021515568A5 (https=)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2019502676A5 (https=)
JPWO2019175223A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2014522850A5 (https=)
JPWO2019175224A5 (https=)
JP2024119853A5 (https=)
JP2010531140A5 (https=)
JP2019534710A5 (https=)
JP2020515577A5 (https=)
JP2021520201A5 (https=)
JP2020528765A5 (https=)
JP2020533965A5 (https=)
JP2020513759A5 (https=)